ASH 2022 | FIGHT-203 trial: pemigatinib in patients with MLNs with FGFR1 rearrangement
Srdan Verstovsek, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses the rationale and results of the FIGHT-203 trial (NCT03011372), which investigated the efficacy of pemigatinib in patients with myeloid/lymphoid neoplasms (MLNs) with a rearrangement in the fibroblast growth factor receptor (FGFR) 1 gene. This study demonstrated that the FGFR inhibitor pemigatinib is extremely effective at controlling and eliminating the disease – and the results of this study have since led to the drug’s approval by the Food and Drug Administration (FDA). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
NS Pharma: Research Funding; AstraZeneca: Research Funding; ItalPharma: Research Funding; Novartis: Consultancy, Research Funding; Incyte: Consultancy, Research Funding; Promedior: Research Funding; CTI BioPharma Corp.: Research Funding; Gilead: Research Funding; Sierra Oncology: Consultancy, Research Funding; Roche: Research Funding; Protagonist Therapeutics: Research Funding; PharmaEssentia: Research Funding; Blueprints Medicines Corp.: Research Funding; Celgene: Consultancy, Research Funding; Genentech: Research Funding; Pragmatist: Consultancy; Constellation Pharmaceuticals: Consultancy.
